Mode
Text Size
Log in / Sign up
N/A N=834 Diagnostic

Automated Detection of Malarial Retinopathy in Patients Diagnosed With Cerebral Malaria

Cerebral Malaria · Malarial Retinopathy

Enrolled (actual)
834
Serious AEs
0.0%
Results posted
Jul 2025
Primary outcome: Primary: Sensitivity and Specificity of ASPIRE to Detect Malarial Retinopathy in Eyes of the Subjects Clinically Diagnosed With CM — 87; 85 Percentage of participants

Study Design & Population

Study type
Interventional
Phase
N/A
Interventions
Automated software for malarial retinopathy detection (Diagnostic_test)
Age
Pediatric, Adult
Sex
All
Sponsor
VisionQuest Biomedical LLC
Primary completion
Apr 2024

Outcome Measures

OutcomeResultp-value
PRIMARY
Sensitivity and Specificity of ASPIRE to Detect Malarial Retinopathy in Eyes of the Subjects Clinically Diagnosed With CM
87; 85
SECONDARY
Positive Predictive Value (PPV) and Negative Predictive Value (NPV) of ASPIRE to Detect Malarial Retinopathy in Eyes of the Subjects Clinically Diagnosed With CM
88; 83

Summary

The focus of the study is performance validation of ASPIRE software device in processing mydriatic retinal images of a patient with clinically diagnosed Cerebral Malaria (CM), to detect malarial retinopathy (MR). The outcome expected is the sensitivity and specificity of ASPIRE in detecting MR in patients with clinical diagnosis of CM, who may be addressed by a physician or ophthalmic specialist with follow-up and/or treatment. The reference standard for detection of MR is based on an adjudicated diagnoses by a panel of three ophthalmic graders (ophthalmologists) trained in the detection of MR in retinal images.

Eligibility Criteria

Inclusion Criteria

  • 1. Pediatric patients under 21 years admitted to any one of the study sites who satisfy the standard clinical case definition of cerebral malaria according to the World health organization (WHO) criteria:
  • Blantyre coma score of ≤2
  • Known positive result of a malaria test for peripheral Plasmodium falciparum parasitemia (blood smear or malaria rapid diagnostic test) 2. Consent provided by parents/caregivers of the eligible pediatric patients

Exclusion Criteria

  • Pediatric patients admitted who satisfy the standard clinical case definition of cerebral malaria, but there is no clinician/nurse available to do an examination within 6 hours of admission, or no consent provided by parents/caregivers.
View full record on ClinicalTrials.gov →

Data sourced from ClinicalTrials.gov (NCT06915285). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication.

Back to search